Orphan Drugs & Rare Diseases- Innovative Strategies for Getting Orphan Drugs to Where They Are Needed

-

The call to treat rare diseases has become increasingly greater around the world than ever before. Supportive organisations including patient groups, national health authorities, health trusts, academia, HTAs, pharmaceutical and biotechnical companies are now progressively growing in numbers and sophistication in their approaches to medicinal care for those with rare and ultra-rare diseases.

SMi’s Orphan Drugs & Rare Diseases conference will present briefings from key opinion leaders, those with hands-on experience of regulating new drug discoveries, companies that have already developed advanced orphan drugs & successfully been granted orphan medicine status and selected experts in the field. Our expert speakers will offer unique insights into cutting-edge international developments taking place in: expanding the reach of medicine to previously untreatable and unreachable patients with rare diseases; different regulatory and policy environments; new drug discoveries; innovative business strategies & funding & financing models, and the importance of partnerships with patient groups and those at the point-of-care.

Key benefits of attending:

• Learn about health technology assessment protocols and market access in the EU and globally
• Network with key regulators of orphan medicines and policy makers for national rare disease treatment
• Discover successful funding, financing and economic models for orphan drug development and translational research
• Analyse industry case studies showing how R&D and market access costs can be reduced
• Understand the latest developments in ultra-rare diseases studies and new medicines for them
• Explore how organisations are merging research, resources and expertise in the race to cure rare diseases

Hear keynote addresses from:

• Dr. Edmund Jessop, Medical Advisor, National Commissioning Group for Highly Specialised Services, NHS
• Josie Godfrey, Head of Policy and Coordination, AGNSS

• Stephen Nutt, Executive Officer, Rare Disease UK

• Carlos R. Camozzi, MD, PhD, MBA, Vice President, Chief Medical Officer, uniQure B.V.

• Marisa Jaconi, Vice-Director and Founder, Swiss Institute of Cell Therapies (SICT)

• Samantha Parker, Director of External Affairs and Rare Disease Partnerships, Orphan Europe


Location:
Copthorne Tara Hotel, London
Scarsdale Place,
Kensington,
Kensington & Chelsea,
London,
W8 5SR
UK


Organizer: SMi Group Ltd

8 Oct 2012



All Upcoming Events
1 2 Next 
PEGS4 May 2015
Nordic Chemical Biology Meeting 20155 May 2015
ISBER5 May 2015
FT US Healthcare and Life Sciences Conference6 May 2015
Pharmacovigilance, Drug Safety and Risk Management11 May 2015
Formulation & Drug Delivery Congress18 May 2015
Cutting-Edge Technologies for Target Validation Conference 201518 May 2015
5th Annual European Food Manufacturing & Safety Summit 201518 May 2015
ADC Summit 201518 May 2015
15th Annual Pain Therapeutics Conference18 May 2015
Clinical Trial Logistics20 May 2015
World Stem Cells & Regenerative Medicine Congress20 May 2015
World Cord Blood Congress20 May 2015
World Biosimilar Congress USA 201527 May 2015
Cell Culture World Congress USA 201527 May 2015
Americas Antibody Congress 201527 May 2015
The American Association of Immunologists30 May 2015
63rd ASMS Conference on Mass Spectrometry and Allied Topics31 May 2015
Biomarkers World Europe2 Jun 2015
European Association of Allergology and Clinical Immunology – EEACI Congress6 Jun 2015
AAPS8 Jun 2015
ESHRE (European Society of Human Reproduction and Embryology)14 Jun 2015
BIO International Convention15 Jun 2015
ACHEMA 201515 Jun 2015
Next Generation Sequencing Data Congress15 Jun 2015
HPLC21 Jun 2015
EuroMedLab Paris 2015, the 21st IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine21 Jun 2015
BioBanking 201522 Jun 2015
Microbiology & Infectious Diseases Asia Congress23 Jun 2015
Pharmacovigilance Europe 2015 - Trending towards a proactive and more vigilant approach23 Jun 2015

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement